Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Common Equity: 2023-2024

Historic Common Equity for CG Oncology (CGON) over the last 2 years, with Dec 2024 value amounting to $733.4 million.

  • CG Oncology's Common Equity rose 28.11% to $687.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $687.6 million, marking a year-over-year increase of 28.11%. This contributed to the annual value of $733.4 million for FY2024, which is 695.76% up from last year.
  • As of FY2024, CG Oncology's Common Equity stood at $733.4 million, which was up 695.76% from -$123.1 million recorded in FY2023.
  • In the past 5 years, CG Oncology's Common Equity ranged from a high of $733.4 million in FY2024 and a low of -$123.1 million during FY2023.
  • Over the past 2 years, CG Oncology's median Common Equity value was $305.1 million (recorded in 2023), while the average stood at $305.1 million.
  • Data for CG Oncology's Common Equity shows a peak YoY spiked of 695.76% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows CG Oncology's Common Equity stood at -$123.1 million in 2023, then surged by 695.76% to $733.4 million in 2024.